Finance
Novo Nordisk sees 'painful' US price cuts for Wegovy as investment in the future
Published by Global Banking & Finance Review®
Posted on February 4, 2026
1 min readLast updated: February 4, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 4, 2026
1 min readLast updated: February 4, 2026
Novo Nordisk's CEO calls US Wegovy price cuts 'painful' but sees them as future investments, increasing drug accessibility amid a tough market.
COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk CEO Mike Doustdar said on Wednesday that the price reductions for its obesity drug Wegovy in the U.S. are "painful" for the company's financial results but he hopes that they will be an investment in the future as many more people will be able to get access to the medicines as a result.
Doustdar was speaking with journalists after the company on Tuesday gave a far worse-than-expected outlook for 2026 and flagged a tough weight-loss market battle ahead as prices come under pressure.
(Reporting by Maggie Fick and Jacob Gronholt-Pedersen, editing by Stine Jacobsen)
Wegovy is a prescription medication developed by Novo Nordisk for chronic weight management in adults with obesity or overweight conditions.
Price cuts refer to reductions in the selling price of a product or service, often aimed at increasing sales volume or market share.
Market outlook refers to the anticipated future trends and conditions in a specific market, including factors like competition, demand, and pricing.
Explore more articles in the Finance category